a multiple dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of mk-8150 (mk-8150-002)

Conditions: Hypertension; Isolated Systolic Hypertension

Summary: this randomized, double-blind, placebo-controlled, multiple-rising-dose study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of mk-8150 in healthy young men, in male participants with mild to moderate hypertension, in elderly male and female participants with mild to moderate hypertension, and in male and female participants with resistant hypertension. a primary study hypothesis is that there is at least one dose that does not increase heart rate (hr) to a clinically meaningful extent in male participants with mild to moderate hypertension and in elderly participants with mild to moderate hypertension on either day 1 or the last day of multiple dosing (daylast), as measured by time-weighted average across 24 hours (twa0-24hrs). the hypothesis is met if mean increase (mk-8150 - placebo) in twa0-24hrs hr in the identified groups is ≤15 beats per minute on day 1 and daylast.

ten panels (panels a-j), consisting of 103 participants in total, will be randomized to receive either mk-8150 or matching placebo. males (18 to 55 years of age, inclusive) with mild to moderate hypertension will be randomized in panels a-d and will receive either mk-8150 or placebo as once daily treatment for 10 consecutive days. elderly males and females (65 to 80 years of age, inclusive) with mild to moderate hypertension will be included in panels e and f and will receive a single dose of either mk-8150 or placebo on study day 1 followed by at least 5 days of wash-out before proceeding to once daily treatment of the same randomized treatment at a lower dose for 10 consecutive days. participants 18 to 65 years of age with resistant hypertension will be enrolled in panels h and will receive in randomized sequences of mk-8150/placebo or placebo/mk-8150 in 2 treatment periods. there will be a minimum 3 weeks washout period between the 2 treatment periods in panel h. healthy males (18 to 55 years of age, inclusive) will be enrolled in panel g and will receive mk-8150 or matching placebo once daily for 28 days. participants randomized to mk-8150 in panel g who meet all of the dose-escalation criteria and have not met any of the hemodynamic stopping criteria will be eligible for dose increases on day 8, day 15, and day 22. if dose escalation criteria are not met (or if the investigator or sponsor elects not to increase the dose), then the participant will continue on the current dose and will be eligible for a dose increase at the next dose-escalation decision day if all dose-escalation criteria are met at that time. male participants (18 to 65 years of age, inclusive) with mild to moderate hypertension will be randomized in panels i and j. in each panel, 18 participants will receive either mk-8150 or matching placebo as once daily treatment for up to 28 consecutive days. participants who are randomized to placebo will receive placebo throughout the study. on days 8, 15 and 22 in both panels i and j, participants will be eligible for dose-escalation, down-dosing, or continuing their current dose depending on their hemodynamic status. participants in panels i and j who meet down-dosing criteria at any time during the study will have their doses reduced to the previous well-tolerated dose level until the next dose-escalation decision day, or through the end of the study, whichever is first.

Eligibility criteria:
inclusion criteria: * hypertensive male participant between 18 to 55 years of age for panels a to d; hypertensive male or female of non-childbearing potential between 65 to 80 years of age for panels e and f; healthy males between 18 to 55 years of age for panel g; hypertensive male or non-childbearing potential female between 18 to 65 years of age (inclusive) for panel h; hypertensive male between 18 to 65 years of age for panels i and j * body mass index (bmi) ≤ 33 kg/m\^2 * in good age appropriate health * no history of clinically significant cardiac disease * nonsmoker and/or has not used nicotine or nicotine-containing products for at least 6 months exclusion criteria: * mentally or legally incapacitated, has significant emotional problems or has a history of a clinically significant psychiatric disorder over the last 5 years * history of stroke, chronic seizures, or a relevant major neurological disorder * history of neoplastic disease (cancer) * unable to refrain from or anticipates the use of any medication, including any non-steroidal anti-inflammatory drug (nsaid) and aspirin-containing products, prescription and non-prescription drugs or herbal remedies for 2 weeks prior to study start up to end of study * anticipates using erectile dysfunction medications during the study * uses or anticipates using organic nitrates during the course of the study (e.g. nitroglycerin, isosorbide mononitrate, isosorbide dinitrate, pentaerythritol) * consumes excessive amounts of alcohol, defined as greater than 3 glasses of alcoholic beverages (1 glass is approximately equivalent to: beer \[284 ml/10 ounces\], wine \[125 ml/4 ounces\], or distilled spirits \[25 ml/1 ounce\]) per day * has had major surgery, donated or lost 1 unit of blood or participated in another investigational study within 4 weeks * history of significant multiple and/or severe allergies (including latex allergy) * current regular user (including recreational use) of any illicit drugs or has a history of drug (including alcohol) abuse within approximately 1 year